CommercialCoverageMedium impact
Drug Policy Criteria Change
Arkansas Blue Cross Blue Shield·AR · Oncology, Hematology·Pharmacy
Effective date
Feb 22, 2026
We identified it
Jun 19, 2026
Summary
Arkansas Blue Cross expanded coverage criteria for three specialty drugs: Omisirge for severe aplastic anemia in patients 6+ years old, Padcev for urothelial carcinoma combinations, and Revuforj for relapsed/refractory AML with NPM1 mutations. These changes align with FDA label updates and NCCN guidelines.
Action Required
Before February 22, 2026: Review current patients on Omisirge, Padcev, and Revuforj to ensure they meet the updated coverage criteria. For Revuforj submissions, ensure documentation of NPM1 mutational status is included in prior authorization requests. Update internal drug coverage references to reflect the expanded indications.